speb/financial-data huggingface dataset:
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Working Capital: 30507000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Write Off: 51000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 3144000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 14357000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 3679000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 74000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 1046000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 24634000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 71499000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 2345000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 50015000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 23000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 2010000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 2033000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 10087000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 870000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 562000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 2376000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 25382000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 7746000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 73509000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 3679000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 51000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 51000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 695000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 69000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 964000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 25382000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 69123000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 385000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 2000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 3177000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 1785000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 71141000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 1814000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 584000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 23037000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 101000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 23588000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Payables: 4347000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 71499000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 69123000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 82447000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 71499000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 2084000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 71568000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 10879000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 32432000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 792000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 1203000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 39928000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — +Operating Expense: 17789000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 5220000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — +Total Revenue: 44295000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 12210000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 2749000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 2749000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 12466000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 12466000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -12495000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -12495000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 12037000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 12037000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -197000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -197000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 1544000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 1544000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 179118374.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 179118943.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Basic EPS: 105.26
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 22.70
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 704000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 11392000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 11392000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -5116000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 63000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 63000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 358000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 1200000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 1200000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 28076000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 28076000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -1078000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 539000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 539000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 661000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 661000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -653000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -546000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -227000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Change In Payable: 403000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -593000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -1997000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 716000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 358000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 76070000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 76070000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 73000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: 0.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 2742000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 2742000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 6898000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2492000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Current Assets: 52700000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 52700000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 17000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 17000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt: 2731000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 2731000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 2748000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 2748000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 9435000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 9435000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 779000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 779000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation: 2352000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 2352000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 2352000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 983000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 2352000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 983000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 179118374.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 179118943.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Diluted EPS: 105.26
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 22.70
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 18854000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 4066000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 28000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 28000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 33000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — EBIT: 23153000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — EBIT: 5161000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — EBITDA: 25505000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — EBITDA: 6144000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: -220000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — End Cash Position: 1200000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -2107000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 2585000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 2585000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 11852000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -47000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -901000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 1749000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill: 574000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 574000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 2661000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 2661000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 12663000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 12663000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 39556000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 39556000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Gross Profit: 37397000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 9718000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: 30000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense: 239000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 102000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 239000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 102000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Interest Income: 1872000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 1872000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -176000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 1466000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Inventory: 7658000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 7658000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 78801000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 78801000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -14145000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 1544000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 1544000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 73000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 0.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 5265000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 5265000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 46000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 46000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 46000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 46000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 0.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 656000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 656000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 19683000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 19683000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 53000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 53000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Minority Interests: 20000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 6000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 0.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 73000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Net Debt: 1531000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 1531000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -8000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Income: 18854000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income: 4066000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 18854000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 4066000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 18834000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 4060000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 18854000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 4066000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 18854000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 4066000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 22914000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 18834000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 4060000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Intangibles Purchase And Sale: -904000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Interest Income: -239000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -102000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -11046000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -892000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 0.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -239000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -102000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: -629000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Net PPE: 27061000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 27061000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -3061000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: -892000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 73409000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 73409000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 46000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 46000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 501000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 501000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 2000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 2000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 656000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 656000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 1769000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 1769000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 25505000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 6144000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Normalized Income: 18854000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 4066000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 16968000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Operating Income: 19608000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Income: 4498000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Operating Revenue: 44295000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 12210000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 179109870.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 1000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 395000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 395000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 75712000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 75712000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 2087000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 2087000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 508000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 508000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -1638000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 490000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 490000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 3545000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 663000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 9492000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 2643000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Payable: 571000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 571000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Properties: 474000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 474000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 1139000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 1139000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 26876000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 26876000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Other Special Charges: -901000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Payables: 4138000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Payables: 4138000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 3291000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 3291000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Pretax Income: 22914000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 5059000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: -22000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: 0.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Intangibles: -1105000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -23973000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -4011000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 3312000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 3312000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 6898000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2492000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 2352000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 983000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 46000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 46000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: 0.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Research And Development: 1134000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 69000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 69000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 62466000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 62466000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of Intangibles: 201000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 12927000000.00
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 950000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 1364000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 3113000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Share Issued: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 179109870.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Special Income Charges: 860000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 76070000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 76070000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 73409000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 73409000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Tax Provision: 4080000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 999000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.18
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.20
NATCOPHARM.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -3726000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Assets: 86308000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 86308000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 76070000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 76070000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Debt: 2794000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 2794000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 76123000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 76123000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Total Expenses: 24687000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 7712000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 10185000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 10185000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 33608000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 33608000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 750000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 750000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 69000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 790000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 790000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 860000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 860000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Work In Process: 1253000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 1253000000.00
NATCOPHARM.NS balance_sheet (annual, 2025-03-31) — Working Capital: 43265000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 43265000000.00
NATCOPHARM.NS income_statement (annual, 2025-03-31) — Write Off: 11000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 5825000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 13289000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 179098361.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 26.84
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2330000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 576000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 576000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 179098361.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 26.84
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 4807000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — EBIT: 5751000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — EBITDA: 6327000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 10959000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 32000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 32000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 4000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income: 4807000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 4807000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 4803000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 4807000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 4807000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 4803000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -32000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -32000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 6327000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 4807000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Income: 5134000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 13289000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 617000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 3559000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 5719000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2330000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 576000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 916000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.16
NATCOPHARM.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 8155000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 6665000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 13630000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 5126000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 17189000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 3196000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 179129233.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 28.94
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 79000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 1035000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 40768000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 86498000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 2552000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1697000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 69667000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 32000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 2528000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 2560000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 17000000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 4303000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 524000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 524000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 179129233.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 28.94
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 5184000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — EBIT: 6268000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — EBITDA: 6792000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 597000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 2602000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 26923000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 11933000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 131000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 131000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 8180000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 89026000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 3196000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 47000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 47000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 627000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 44000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 5000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 1493000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income: 5184000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 5184000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 5179000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 5184000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 5184000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 5179000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -131000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -131000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 26923000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 83896000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 1176000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 32000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 6792000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 5184000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Income: 5268000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 13630000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 3428000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 1944000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 86140000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 2005000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 690000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 1000000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 4138000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 24371000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 102000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 39733000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Payables: 6499000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 6137000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1697000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 524000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 86498000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 83896000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 958000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.16
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 104301000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 86498000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 2607000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 86542000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 8362000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 17759000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 34634000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 759000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 1373000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 52667000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 4017000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 6473000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 179078014.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 8.46
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1331000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 462000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 462000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 179078014.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 8.46
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 1515000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — EBIT: 1706000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — EBITDA: 2168000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 5142000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 95000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 95000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 2000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income: 1515000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 1515000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 1513000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 1515000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 1515000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 1513000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -95000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -95000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 2168000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 1515000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Income: 1125000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 6473000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 581000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 1961000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 1611000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1331000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 462000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 207000000.00
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.13
NATCOPHARM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 5348000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 21579000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 5072000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 40783000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 7391000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 4093000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 4093000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 8812000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 8812000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 3352000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 3352000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 179077540.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 14.96
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 1200000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -3911000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 75000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 75000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 358000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 1989000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 1989000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 28709000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 28709000000.00